Benjamin F. Edwards & Company’s United Therapeutics UTHR Stock Holding History

Benjamin F. Edwards & Company’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$109K	Buy	343 +42	+14%	+$11.1K	﹤0.01%	1089
2024 Q1	$69K	Buy	301 +117	+64%	+$26.4K	﹤0.01%	1209
2023 Q4	$40K	Buy	184 +11	+6%	+$2.54K	﹤0.01%	1310
2023 Q3	$39K	Hold	173	–	–	﹤0.01%	1126
2023 Q2	$38K	Buy	173 +6	+4%	+$1.33K	﹤0.01%	1149
2023 Q1	$37K	Sell	167 -1,145	-87%	-$282K	﹤0.01%	1167
2022 Q4	$365K	Buy	1,312 +1,153	+725%	+$291K	0.02%	547
2022 Q3	$33K	Hold	159	–	–	﹤0.01%	1157
2022 Q2	$37K	Buy	159 +75	+89%	+$15.2K	﹤0.01%	1115
2022 Q1	$15K	Buy	+84	New	+$16K	﹤0.01%	1289

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Benjamin F. Edwards & Company's UTHR Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its United Therapeutics (UTHR) stake by 14% in Q2 2024, buying an estimated $11.1K and bringing the position to 343 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Benjamin F. Edwards & Company first reported a position in UTHR in Q1 2022 and has held it in 10 quarters since. The position peaked at $365K in Q4 2022. 568 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

Benjamin F. Edwards & Company held 343 shares of United Therapeutics worth $109K as of Q2 2024.
Benjamin F. Edwards & Company bought 42 United Therapeutics shares in Q2 2024, an estimated $11.1K.
United Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1089 holding.
Benjamin F. Edwards & Company first reported a position in United Therapeutics in Q1 2022 and has held it in 10 quarters since.
Benjamin F. Edwards & Company's United Therapeutics position peaked at $365K in Q4 2022.
568 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.